|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/21/22 CVS Health Corp. 8-K:5,8,9 11/17/22 11:425K Shearman & Sterling LLP |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 31K 2: EX-3.1 By-Laws of Cvs Health Corporation HTML 181K 6: R1 Cover HTML 47K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- ss1535680_8k_htm XML 15K 8: EXCEL IDEA Workbook of Financial Reports XLSX 8K 4: EX-101.LAB XBRL Labels -- cvs-20221117_lab XML 96K 5: EX-101.PRE XBRL Presentations -- cvs-20221117_pre XML 64K 3: EX-101.SCH XBRL Schema -- cvs-20221117 XSD 13K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 32K 11: ZIP XBRL Zipped Folder -- 0000947871-22-001199-xbrl Zip 64K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | i November 17, 2022 |
(Exact name of registrant as specified in its charter)
| i Delaware | i 001-01011 | i 05-0494040 | ||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) |
(IRS Employer Identification No.) | ||||||
i One CVS Drive, i Woonsocket, i Rhode Island i 02895
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: i (401) i 765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| i Common Stock, par value $0.01 per share | i CVS | i New York Stock Exchange | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | i ☐ | ||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
Section 5 - Corporate Governance and Management
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On November 17, 2022, the Board of Directors of CVS Health Corporation (the “Company”) amended, effective immediately, the by-laws (the “By-laws”) of the Company to (a) revise Section 1.10 with respect to the notification and other requirements related to nominations of directors and solicitations of proxies, including requiring compliance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and (b) incorporate ministerial, clarifying and conforming changes.
The foregoing description of the amendments to the By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, as amended and restated, a copy of which is attached as Exhibit 3.1 and incorporated by reference herein.
Section 8 – Other Events
Item 8.01 Other Events
On November 17, 2022, the Board of Directors of the Company approved the 2022 Repurchase Program pursuant to which the Company is authorized to repurchase up to $10 billion of shares of the Company’s common stock (including brokers’ fees and commissions) after the full utilization of the Company’s existing 2021 Repurchase Program authorization.
The 2022 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market purchases, privately negotiated transactions, accelerated share repurchase transactions, and/or other derivative transactions.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
| Exhibit | Description | |
| 3.1 | By-laws of CVS Health Corporation, as amended and restated, effective November 17, 2022. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document). |
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CVS HEALTH CORPORATION | ||
| Date: November 21, 2022 | By: | /s/ Colleen M. McIntosh |
| Colleen M. McIntosh | ||
|
Senior Vice President, Secretary and Chief Governance Officer | ||
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/21/22 | None on these Dates | ||
| For Period end: | 11/17/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/07/24 CVS Health Corp. 10-K 12/31/23 166:28M 8/02/23 CVS Health Corp. S-8 8/02/23 6:235K Shearman & Sterling LLP 5/02/23 CVS Health Corp. S-8 5/02/23 5:247K Shearman & Sterling LLP 3/29/23 CVS Health Corp. S-8 3/29/23 5:195K Shearman & Sterling LLP 2/08/23 CVS Health Corp. 10-K 12/31/22 138:26M |